Evolving Your FSP Relationships to Achieve the Maximum Return

Abstract: The drug development lifecycle can be predictably unpredictable, as mergers and acquisitions, interim results, DSMB decisions, reorganization, and evolving technology can all change the course of any plan in short order. Sponsors rely on the ability of Clinical Research Organization (CRO) partners to provide scalability and global reach in support of their core teams.

FSP relationships however, can go beyond the ability to quickly ramp up and down. Explore with us, as we discuss how Sponsors who leverage FSP partners across multiple interdependent functional lines achieve the maximum benefit and the increasing importance of the way that new innovations and technology continue to change the way we work and the future skill sets needed.

Attendees will learn:

  • How to achieve maximum benefit from FSP relationships
  • The need for diversification in the vendor portfolio
  • The potential for nimble adaptation and growth in long-term FSP partnerships
  • Possibilities for investing and growing together with your FSP partner
  • Implications and potential solutions for IR35 compliance


Donnelle LaDouceur, Director of Functional Service Solutions

Liz Valley-Burr, Manager of Project and Account Management

Alan Nicolle, Senior Director of European & South Africa Operations

Fill out the form below to view the webinar.



Read On

Update Disclosure Policy for EU Clinical Trial Regulation & ICMJE

By Karim Ibazatene, Associate Director, Transparency 

Expedited Drug Development and Review Pathways - MMS Holdings Holdings

by Amanda Beaster, Ph.D. and Janiel Shields

Webinar: RWD & Using RWE in Drug Development - MMS Holdings Holdings